Skip to main content
Kamada Ltd. logo

Kamada Ltd. — Investor Relations & Filings

Ticker · KMDA ISIN · IL0010941198 TA Manufacturing
Open in API
Filings indexed 829 across all filing types
Latest filing 2026-03-23 Director's Dealing
Country IL Israel
Listing TA KMDA

About Kamada Ltd.

https://www.kamada.com

Kamada Ltd. is a vertically integrated global biopharmaceutical company specializing in plasma-derived protein therapeutics. The company develops, manufactures, and commercializes a portfolio of products for rare and serious conditions, with a focus on therapeutic areas such as Alpha-1 Antitrypsin Deficiency (AATD) and Cytomegalovirus (CMV) prevention in transplant patients. Kamada utilizes a proprietary platform technology for advanced protein extraction and purification from human plasma. In addition to its marketed products, the company maintains a development pipeline of new therapies, including an inhaled treatment for AATD.

Recent filings

Filing Released Lang Actions
FORM 3-INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES-Davidi Ishay
Director's Dealing Classification · 95% confidence The document is a U.S. SEC Form 3 filed under Section 16(a) of the Securities Exchange Act of 1934, detailing a director’s and 10% owner’s beneficial ownership of securities (initial statement of beneficial ownership, including shares and options). This is an insider transaction reporting form, matching the ‘Director’s Dealing’ category.
2026-03-23 English
FORM 3-INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES-Davidi Ishay
Director's Dealing Classification · 85% confidence The document is a TASE/ISA immediate report under Regulation 5 announcing the attachment of a Form 3 filing by Ishay Davidi. A Form 3 is an SEC insider beneficial ownership statement (initial insider holding). This falls squarely under director/executive personal share transactions (insider dealing). Therefore, it should be classified as DIRS.
2026-03-23 English
Other Report or Announcement
Director's Dealing Classification · 92% confidence The document is a U.S. SEC Form 3 “Initial Statement of Beneficial Ownership of Securities,” filed under Section 16(a) of the Securities Exchange Act of 1934. It reports personal shareholdings and option grants by an officer/director. This corresponds to an insider trading disclosure by a company director or executive. Therefore, it falls under the Director’s Dealing category (insider trades).
2026-03-21 English
Other Report or Announcement
Director's Dealing Classification · 85% confidence The document is an immediate report under Israeli Securities Regulations (Periodic and Immediate Reports of Foreign Corporation) attaching a Form 3 filed with the U.S. SEC by an insider (Eran Nir). A Form 3 is an initial beneficial ownership statement for directors/executives, which falls under insider transactions reporting. Therefore, this is a Director’s Dealing report.
2026-03-21 English
Other Report or Announcement
Director's Dealing Classification · 90% confidence The document is a United States SEC Form 3 “Initial Statement of Beneficial Ownership of Securities,” filed under Section 16(a) of the Securities Exchange Act, detailing the insider’s direct and indirect holdings and option grants. This corresponds to insider transactions by a company director/officer. Therefore, it is categorized as a Director’s Dealing filing (insider share transactions).
2026-03-21 English
Other Report or Announcement
Director's Dealing Classification · 92% confidence The document is an Israeli TASE immediate report under Regulation 5, attaching a Form 3 filed with the SEC by Yael Brenner. Form 3 is the initial insider beneficial ownership report, i.e. a personal share transaction by an officer/director. This clearly fits the Director’s Dealing category.
2026-03-21 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.